Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial

Authors: Mark D. Linch, Yien Ning Sophia Wong, Robert Jones, Peter Sankey, Debra H. Josephs, Simon J. Crabb, John Staffurth, Anjali Zarkar, Laura White, Marian Duggan, Giulia Pellizzari, Graham Wheeler, Sandy Beare, Hayley Cartwright, Josep Linares, Ayse Akarca, Sergio A. Quezada, Leah Ensell, John Hartley, Gerhardt Attard, Joanna Burr, Anuradha Jayaram, Bihani Kularatne, Mahaz Kayani, Moon Chung, Colin C. Pritchard, Alex Freeman, Aiman Haider, Teresa Marafioti

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-lb004

Source: Full article